Patient characteristics before and after propensity score matching. by Anna D. Ware (19688153)

Subjects:

Unadjusted and adjusted odds ratios (95% confidence interval) for associations between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute th... by Anna D. Ware (19688153)

Subjects:

Forest plot displaying the association (odds ratio [95% CI]) between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disor... by Anna D. Ware (19688153)

Subjects:

Frequency of post-COVID-19 acute thromboembolic disorders among aspirin users vs. non-users within 12 months following index date. by Anna D. Ware (19688153)

Subjects:

δ¹⁵N in <i>Fucus spiralis</i> vs. <i>F. vesiculosus.</i> by Antonio Bode (1473376)

Subjects:

Changes associated with kidney fibrosis and effects of MN705 treatment on TGF- by Wencheng Jin (13136262)

Aβ and vGlut2 staining of 6-, 9-, and 12-month dLGN sections show significant plaque load and accelerated loss of retinal ganglion cell axon terminals in the 5xFAD mice. by Shaylah McCool (20818280)

Changes related to kidney staining in UUO mouse model. by Wencheng Jin (13136262)

Changes associated with kidney fibrosis in TGF- by Wencheng Jin (13136262)

The screening process of MN705. by Wencheng Jin (13136262)

Validation of MN705 treatment effects in human proximal tubular epithelial cells during TGF- by Wencheng Jin (13136262)

Effect of MN705 treatment on TGF- by Wencheng Jin (13136262)

Modeling the relationship between cancer level in hemolymph and MarBTN in tank eDNA. by Rachael M. Giersch (22331947)

Renal outcomes of both treatment groups. by Marwan El-Deyarbi (21688492)

“…</p><p>Results</p><p>During a mean follow-up of 11.9 months, 40.4% of the participants in the intervention group (31.6% in the control group) achieved diabetes control (HbA1c < 7%), with a significant mean difference of −0.36% in HbA1c levels between the groups (95% CI: −0.54 – −0.19, P < 0.01). …”

Supplementary Tables 1–8. by Juliane F. Tampé (19976538)

Subjects:

Renal (urea and creatinine) (a, b) and Liver function (ALT and AST) (c, d) test in serums of different experimental groups and body weight changes (e) on day 10. by Omid Mehrpour (9385929)

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects: